In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.
Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.
How to Write a New York Times Op-Ed in Three Easy Steps | Human Events
The Situation With Kim Davis | RedState
'These are terrible times': Waco Police Department issues poignant, must-read mission statement
10mm Underwood Extreme Penetrators Vs Bulletproof Glass - Bearing Arms - 10mm, Underwood, Video
Katie Pavlich - Exposing The Black Lives Matter Movement For What It Is: Promotion of Cop Killing
Megyn Kelly gets angry: Why don’t the left’s “civility” rules apply to Black Lives Matter protesters? - Hot Air
Carrie Schwab Pomerantz - Can You Borrow From Your IRA?